| Drug Name |
Urokinase |
| Drug ID |
BADD_D02320 |
| Description |
Urokinase is an endogenous peptide that is cleaved in the presence of plasmin between lysine 158 and isoleucine 159 to yield active urokinase.[A191943] Urokinase remains connected between these 2 chains by a sulfhydryl bond.[A191943]
Urokinase was granted FDA approval on 16 January 1978.[L12138] |
| Indications and Usage |
In Canada, urokinase is indicated for lysis of acute massive pulmonary emboli, acute thrombi obstructing coronary arteries, occlusive thromboemboli in peripheral arteries and grafts, and restoration of patency to intravenous catheters.[L12141] |
| Marketing Status |
approved; investigational; withdrawn |
| ATC Code |
B01AD04 |
| DrugBank ID |
DB00013
|
| KEGG ID |
D03341
|
| MeSH ID |
D014568
|
| PubChem ID |
Not Available
|
| TTD Drug ID |
Not Available
|
| NDC Product Code |
Not Available |
| UNII |
83G67E21XI
|
| Synonyms |
Urokinase-Type Plasminogen Activator | Urokinase Type Plasminogen Activator | Plasminogen Activator, Urokinase-Type | U-Plasminogen Activator | U Plasminogen Activator | U-PA | Urinary Plasminogen Activator | Urokinase | Renokinase | Abbokinase | Kidney Plasminogen Activator | Single-Chain Urokinase-Type Plasminogen Activator | Single Chain Urokinase Type Plasminogen Activator |
